Neurocrine Biosciences, Inc.NBIXNASDAQ
LOADING
|||
EV to Sales: Discounted Valuation
Trending lower, below historical average, structural decline.
Left:
||||
Enterprise value to sales ratio
Latest
5.91
↓ 90% below average
Average (9y)
56.38
Historical baseline
Range
High:238.04
Low:5.91
CAGR
-33.7%
Structural decline
| Period | Value | Change |
|---|---|---|
| 2024 | 5.91 | -14.5% |
| 2023 | 6.92 | -10.0% |
| 2022 | 7.69 | +6.8% |
| 2021 | 7.20 | -17.7% |
| 2020 | 8.75 | -32.6% |
| 2019 | 12.98 | -17.0% |
| 2018 | 15.65 | -63.6% |
| 2017 | 42.95 | -80.3% |
| 2016 | 217.77 | -8.5% |
| 2015 | 238.04 | - |